Proprietary probiotic blend may be effective adjuvant to dyspepsia treatment

Photo © iStockphoto.com/Artem_Furman

A recent study found that a proprietary blend of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052, marketed as Lacidofil Strong by Lallemand, may be an effective adjuvant to antibiotics for the treatment of dyspepsia. Antibiotics are used to eradicate Helicobacter pylori, which is the recommended way to provide relief. In the study, 90 patients with dyspepsia were given 30 mg lansoprazole administered twice daily, 1,000 mg amoxicillin administered twice daily, and 1 g clarithromycin modified-release formulation administered once daily for 14 days along with either placebo or the probiotic blend during 14-day treatment period and an additional four weeks.

Results showed that subjects taking the probiotic in addition to standard therapy saw H. pylori eradication rates of 90.9% compared to 75% in those given placebo. Probiotic supplementation was also shown to significantly reduce treatment side effects such as bloating, nausea, and bitter taste. After 14 days of treatment, subjects in the probiotic group had lower scores on a gastrointestinal symptom rating scale and higher SF-36 health-related quality of life scores compared to placebo.

Reference

1. Kiattiweerasak, A.; Aumpan, N.; Chonprasertsuk, S.; Pornthisarn, B.; Siramolpiwat, S.; Bhanthumkomol, P.; Nunanan, P.; Issariakulkarn, N. et al. Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: a double-blind, randomized, placebo-controlled study. Front. Gastroenterol, 2023, 2. DOI: 10.3389/fgstr.2023.1245993